Advertisement

Is everolimus linked to metabolic syndrome in liver transplant recipients?

  • Εvangelos CholongitasEmail author
  • Argyro Koukoufiki
  • Chrysoula Pipili
  • Nikolaos Antoniadis
  • Ioannis Fouzas
  • Anna-Bettina Haidich
  • Ioannis Goulis
Original Article
  • 6 Downloads

Abstract

Background

As the mortality rates after liver transplantation (LT) have been reduced, the attention has shifted to additional conditions which still compromise the quality of life and the survival of these patients, such as the post-LT metabolic syndrome (MS). In order to determine the prevalence and the factors associated with the post-LT MS, we carried out the present study.

Methods

One hundred and six LT recipients, after completing at least 1 year follow up after LT, were included in the study. Data on clinical, laboratory parameters and immunosuppressive therapy before and after LT were recorded. MS was defined as per current diagnostic criteria.

Results

MS was prevalent in 47.2% (50 of 106 patients) and was not associated with the LT indications and the time period after LT. Univariate analysis showed that history of diabetes mellitus before (odds ratio [OR] 3.2, 95% confidence interval [CI] 1.046–9.918, p = 0.042) and after LT (OR 6.03, 95% CI 2.18–16.67, p = 0.001), the age at the time of baseline visit (OR 1.077, 95% CI 1.033–1.124, p = 0.001) and the everolimus-based immunosuppression (OR 1.23, 95% CI 1.003–1.33, p = 0.019) were significantly associated with MS. Notably, everolimus administration was the only factor independently associated with the presence of post-LT MS (OR 1.026, 95% CI 1.004–1.047, p = 0.019). More specifically, everolimus was linked to the presence of arterial hypertension (OR 1.02, 95% CI 1.0–1.03, p = 0.05) and hyperlipidemia (OR 2.87, 95% CI 1.28–6.56, p = 0.011).

Conclusions

Our study demonstrated for the first time that everolimus was independently associated with post-LT MS. Nevertheless, more robust studies are required to confirm these findings.

Keywords

Complications Diabetes mellitus Everolimus Immunosuppression Liver transplantation Mammalian target of rapamycin inhibitor 

Notes

Compliance with ethical standards

Conflict of interest

EC,AK, CP, NA,IF, A-BH, and IG declare that they have no conflict of interest.

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was not supported by external institution or agency. Informed consent was obtained from all individual participants included in the study.

Disclaimer

The authors are solely responsible for the data and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, or the printer/publishers are responsible for the results/findings and content of this article.

References

  1. 1.
    De Mare-Bredemeijer EL, Metselaar HJ. Optimization of the use of calcineurin inhibitors in liver transplantation. Best Pract Res Clin Gastroenterol. 2012;26:85–95.CrossRefGoogle Scholar
  2. 2.
    Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 2005;11:497–503.CrossRefGoogle Scholar
  3. 3.
    Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.CrossRefGoogle Scholar
  4. 4.
    Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation. 2012;94:659–68.CrossRefGoogle Scholar
  5. 5.
    Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734–45.CrossRefGoogle Scholar
  6. 6.
    Satapathy SK, Charlton MR. Posttransplant metabolic syndrome: new evidence of an epidemic and recommendations for management. Liver Transpl. 2011;17:1–6.CrossRefGoogle Scholar
  7. 7.
    Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben AZ. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 2011;17:15–22.CrossRefGoogle Scholar
  8. 8.
    Thoefner LB, Rostved AA, Pommergaard HC, Rasmussen A. Risk factors for metabolic syndrome after liver transplantation: a systematic review and metaanalysis. Transplant Rev (Orlando). 2018;32:69–77.CrossRefGoogle Scholar
  9. 9.
    Madhwal S, Atreja A, Albeldawi M, Lopez R, Post A, Costa MA. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl. 2012;18:1140–6.CrossRefGoogle Scholar
  10. 10.
    Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.Google Scholar
  11. 11.
    Αmerican Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62–9.CrossRefGoogle Scholar
  12. 12.
    Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–95.Google Scholar
  13. 13.
    Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47.CrossRefGoogle Scholar
  14. 14.
    Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl. 2008;14:1648–54.CrossRefGoogle Scholar
  15. 15.
    Jiménez-Pérez M, González-Grande R, Omonte Guzmán E, Amo Trillo V, Rodrigo López JM. Metabolic complications in liver transplant recipients. World J Gastroenterol. 2016;22:6416–23.CrossRefGoogle Scholar
  16. 16.
    Durand F. How to improve long-term outcome after liver transplantation? Liver Int. 2018;38 Suppl 1:134–8.CrossRefGoogle Scholar
  17. 17.
    Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant. 2012;12:1855–65.CrossRefGoogle Scholar
  18. 18.
    De Simone P, Fagiuoli S, Cescon M, et al. Use of everolimus in liver transplantation: recommendations from a working group. Transplantation. 2017;101:239–51.CrossRefGoogle Scholar
  19. 19.
    Charlton M, Rinella M, Patel D, McCague K, Heimbach J, Watt K. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study. Transplantation. 2017;101:2873–82.CrossRefGoogle Scholar
  20. 20.
    Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727–43.CrossRefGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2019

Authors and Affiliations

  • Εvangelos Cholongitas
    • 1
    • 2
    Email author
  • Argyro Koukoufiki
    • 1
  • Chrysoula Pipili
    • 3
  • Nikolaos Antoniadis
    • 4
  • Ioannis Fouzas
    • 4
  • Anna-Bettina Haidich
    • 5
  • Ioannis Goulis
    • 1
  1. 1.4th Department of Internal MedicineMedical School of Aristotle University, Hippokration General Hospital of ThessalonikiThessalonikiGreece
  2. 2.First Department of Internal Medicine, Laiko General HospitalMedical School of National and Kapodistrian University of Athens, Laiko General HospitalAthensGreece
  3. 3.Renal Clinical FellowQueen Elizabeth University HospitalGlasgowUK
  4. 4.Department of Transplant SurgeryAristotle University of ThessalonikiThessalonikiGreece
  5. 5.Department of Hygiene and EpidemiologyMedical School of Aristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations